{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:51:02Z","timestamp":1782121862583,"version":"3.54.5"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>This study aimed to systematically evaluate the efficacy and safety of different doses of domperidone (DOM) combined with esomeprazole (ESM) in the treatment of reflux esophagitis, providing a basis for precise clinical medication. This prospective single-center study enrolled a total of 376 eligible patients with reflux esophagitis (intention-to-treat [ITT] population) between January 2022 and December 2024, among whom 361 completed the full treatment course (per-protocol [PP] population). A total of 361 patients were randomly divided into four groups: control group (oral ESM, n\u2009=\u200990), low-dose group (oral ESM\u2009+\u20095\u00a0mg DOM, n\u2009=\u200992), medium-dose group (oral ESM\u2009+\u200910\u00a0mg DOM, n\u2009=\u200991), and high-dose group (oral ESM\u2009+\u200915\u00a0mg DOM, n\u2009=\u200988), all for an 8-week duration. The primary outcome was the endoscopic remission rate at 8\u00a0weeks, defined as the achievement of Los Angeles classification grade 0 or A (ITT and PP population). Secondary outcomes (PP population) included changes in symptom scores (Gastroesophageal Reflux Disease Questionnaire, Reflux Symptom Index, Reflux Disease Questionnaire), quality of life (GERD-Health Related Quality of Life scale, EuroQol Five-Dimension Five-Level Scale), high-resolution esophageal manometry parameters, 24-hour impedance-pH monitoring indices, serum inflammatory cytokine levels, and the incidence of adverse events. The medium-dose DOM combination group demonstrated the most favorable efficacy across all key endpoints. Its endoscopic remission rate was significantly higher than that of the other three groups (P\u2009&amp;lt;\u20090.05). The results of the ITT analysis were highly consistent with the PP analysis. In the ITT population, the medium-dose group demonstrated a significantly superior endoscopic remission rate (94.68%) compared to the other three groups (P\u2009&amp;lt;\u20090.05). This finding was corroborated by the PP analysis, which also showed the optimal efficacy in the medium-dose group (97.80%). Concurrently, this group exhibited the most pronounced improvements in symptom scores and quality of life, the greatest recovery in esophageal motility parameters, the most significant reduction in all types of reflux episodes, and the greatest decrease in inflammatory cytokine levels (all P\u2009&amp;lt;\u20090.05). The high-dose group ranked second in efficacy, while the low-dose group showed superiority over the control group only in partial indicators. Although there was no significant difference in the incidence of adverse events as reported in the study, the overall event incidence and the increasing trend among different groups suggest the possible existence of a dose\u2013response relationship, especially in the high-dose group. Based on standard esomeprazole therapy, the addition of medium-dose DOM (10\u00a0mg three times daily) synergistically improves reflux control, mucosal healing, motility recovery, and inflammatory status. This dose achieves an optimal balance between efficacy and safety, providing high-level evidence for implementing individualized and precise medication strategies in clinical practice. Although overall adverse event rates did not differ significantly among groups, a dose-dependent trend was observed. Higher doses offer no additional benefit and may increase safety concerns.<\/jats:p>","DOI":"10.1093\/dote\/doag053","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:34:25Z","timestamp":1779190465000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of different domperidone dosages on reflux esophagitis treated with esomeprazole: a randomized controlled trial"],"prefix":"10.1093","volume":"39","author":[{"given":"Wencui","family":"Niu","sequence":"first","affiliation":[{"name":"Nutrition Department, Beijing Hospital of Integrated Traditional Chinese and Western Medicine , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Bao","sequence":"additional","affiliation":[{"name":"Cadre Diagnosis and Treatment Department, PLA General Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhao","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Beijing Hospital of Integrated Traditional Chinese and Western Medicine , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026062205215757600_ref1","first-page":"214","article-title":"Gastroesophageal reflux disease (GERD)","volume":"115","author":"Clarrett","year":"2018","journal-title":"Mo Med"},{"key":"2026062205215757600_ref2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10388-018-0649-1","article-title":"Clinical, endoscopic, and histologic characteristics of lymphocytic esophagitis: a systematic review","volume":"16","author":"Habbal","year":"2019","journal-title":"Esophagus"},{"key":"2026062205215757600_ref3","doi-asserted-by":"publisher","first-page":"e093108","DOI":"10.1136\/bmjopen-2024-093108","article-title":"Health economics evaluation of diagnostic strategies for gastro-oesophageal reflux disease with reflux symptoms in China: a modelling study","volume":"15","author":"Yan","year":"2025","journal-title":"BMJ Open"},{"key":"2026062205215757600_ref4","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci Rep"},{"key":"2026062205215757600_ref5","first-page":"263","article-title":"The pathogenesis of gastroesophageal reflux disease","volume":"8","author":"Souza","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026062205215757600_ref6","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis","volume":"28","author":"Lee","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2026062205215757600_ref7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","article-title":"Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease","volume":"54","author":"Miwa","year":"2019","journal-title":"J Gastroenterol"},{"key":"2026062205215757600_ref8","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.18502\/ijph.v49i12.4807","article-title":"Efficacy and safety of esomeprazole for the treatment of reflux symptoms in patients with gastroesophageal reflux disease: a systematic review and meta-analysis","volume":"49","author":"Hou","year":"2020","journal-title":"Iran J Public Health"},{"key":"2026062205215757600_ref9","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/jcm11185268","article-title":"Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Zamani","year":"2022","journal-title":"J Clin Med"},{"key":"2026062205215757600_ref10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026062205215757600_ref11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","article-title":"The endoscopic assessment of esophagitis: a progress report on observer agreement","volume":"111","author":"Armstrong","year":"1996","journal-title":"Gastroenterology"},{"key":"2026062205215757600_ref12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut"},{"key":"2026062205215757600_ref13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3748\/wjg.v29.i5.773","article-title":"Management of gastro-esophageal reflux disease: practice-oriented answers to clinical questions","volume":"29","author":"Frazzoni","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026062205215757600_ref14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5056\/jnm14014","article-title":"Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico","volume":"20","author":"Zavala-Gonz\u00e1les","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"2026062205215757600_ref15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/lio2.799","article-title":"Utility of reflux finding score and reflux symptom index in diagnosis of laryngopharyngeal reflux disease","volume":"7","author":"Abraham","year":"2022","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"2026062205215757600_ref16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-230X-14-17","article-title":"Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition?","volume":"14","author":"Rey","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"2026062205215757600_ref17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1442-2050.2007.00658.x","article-title":"The development of the GERD-HRQL symptom severity instrument","volume":"20","author":"Velanovich","year":"2007","journal-title":"Dis Esophagus"},{"key":"2026062205215757600_ref18","doi-asserted-by":"publisher","first-page":"675523","DOI":"10.3389\/fpubh.2021.675523","article-title":"Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Public Health"},{"key":"2026062205215757600_ref19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jval.2018.01.020","article-title":"Does selecting covariates using factor analysis in mapping algorithms improve predictive accuracy? A case of predicting EQ-5D-5L and SF-6D utilities from the Women\u2019s Health Questionnaire","volume":"21","author":"Kaambwa","year":"2018","journal-title":"Value Health"},{"key":"2026062205215757600_ref20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s11136-023-03420-2","article-title":"Normative profile of the EQ-5D-5L dimensions, EQ-5D-5L index and EQ-VAS scores for the general Thai population","volume":"32","author":"Kangwanrattanakul","year":"2023","journal-title":"Qual Life Res"},{"key":"2026062205215757600_ref21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5056\/jnm23130","article-title":"On-demand versus continuous maintenance treatment with a proton pump inhibitor for mild gastroesophageal reflux disease: a prospective randomized multicenter study","volume":"29","author":"Jung","year":"2023","journal-title":"J Neurogastroenterol Motil"},{"key":"2026062205215757600_ref22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.21037\/tgh-24-168","article-title":"Drug treatment strategies for erosive esophagitis in adults: a narrative review","volume":"10","author":"Shibli","year":"2025","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2026062205215757600_ref23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.17219\/acem\/171001","article-title":"A comparison of different symptomatic reflux esophagitis treatments: a real-world study","volume":"32","author":"Di Mario","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"2026062205215757600_ref24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/jama.2011.626","article-title":"Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial","volume":"305","author":"Galmiche","year":"2011","journal-title":"JAMA"},{"key":"2026062205215757600_ref25","doi-asserted-by":"publisher","first-page":"711500","DOI":"10.3389\/fphar.2021.711500","article-title":"New developments in prokinetic therapy for gastric motility disorders","volume":"12","author":"Camilleri","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026062205215757600_ref26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21873\/invivo.13056","article-title":"Elevated pro-inflammatory cytokine levels in acute reflux esophagitis are reduced by 1,25 dihydroxy vitamin D3","volume":"37","author":"Wei","year":"2023","journal-title":"In Vivo"},{"key":"2026062205215757600_ref27","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.3892\/etm.2019.7978","article-title":"Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin","volume":"18","author":"Deng","year":"2019","journal-title":"Exp Ther Med"},{"key":"2026062205215757600_ref28","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1097\/MS9.0000000000000723","article-title":"Lack of knowledge regarding the misuse of domperidone in Pakistan and its serious consequences: short communication","volume":"85","author":"Kalwar","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"2026062205215757600_ref29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1540\/jsmr1965.16.37","article-title":"Effect of domperidone on gastric movement and blood flow in dog (author\u2019s transl)","volume":"16","author":"Fujii","year":"1980","journal-title":"Nihon Heikatsukin Gakkai Zasshi"},{"key":"2026062205215757600_ref30","first-page":"42","article-title":"Research progress of proton pump inhibitors in the treatment of gastroesophageal reflux disease","volume":"08","author":"Li","year":"2021","journal-title":"Chin J Gastro Reflux Dis (Electronic Edition)"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag053\/68505699\/doag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag053\/68505699\/doag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:22:06Z","timestamp":1782120126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag053\/8705248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag053","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,12]]},"article-number":"doag053"}}